ClinicalTrials.gg
TerminatedNCT03693625Updated Sep 25, 2020Results posted

A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study

A Phase 2 interventional study of GDC-0853 in Urticaria, sponsored by Genentech, Inc.. Terminated at 10 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-09-25.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Why this study was terminated
Recruitment was stopped after an interim analysis of the parent GS39684 study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies in Urticaria with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Urticaria · United States.

Enrollment
21st of 37
31 · median 39
Started
2018
the only one that year
Phase 2
16 of 47
2 open now
Registered
31st of 47
by date
Lead sponsor
3 of 47
Genentech, Inc.

Among the 47 studies in Urticaria with a site in United States, this one is the 21st largest by enrollment of the 37 interventional ones that give a count, is the only one that started in 2018, is one of 16 in phase 2, and was the 31st registered.

Urticaria

148 studies on the registry are indexed under Urticaria; 20 are open to participants now.

Browse Urticaria studies →

Open to participants now

4 of the 47 studies in Urticaria with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Urticaria studies recruiting now, 3 (25%) set no upper age limit and 6 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Urticaria with a site in United States, or all of them as a file.
02

Study summary

This is a Phase II, multicenter, open-label extension (OLE) study to evaluate the long-term safety and efficacy of fenebrutinib in participants with Chronic Spontaneous Urticaria (CSU) who have completed the treatment period in a fenebrutinib CSU parent study. Participants may enroll in this OLE study at any time after completing the treatment period of the parent study. Participants will receive open-label fenebrutinib at a dose of 200 milligram (mg) orally twice a day. Treatment may continue until the end of the study.

03

Conditions studied

  • Urticaria

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to comply with the study protocol, in the investigator's judgment
  • Completion of the treatment period as specified in the parent study
  • Acceptable demonstration of tolerance to study drug during the parent study as determined by the investigator or Medical Monitor
  • For participants receiving treatment with proton-pump inhibitors (PPIs) or H2-receptor antagonists (H2RAs), agreement to maintain treatment at a stable dose for the first 12 weeks of the study
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use measures, and agreement to refrain from donating eggs
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm

Exclusion criteria

Exclusion Criteria

  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 4 weeks after the final dose of fenebrutinib
  • Treatment with any agent or live/attenuated vaccine in the preceding 6 weeks
  • Any signs or symptoms of infection judged by the investigator to be since completing the treatment period of the parent study
  • Any significant changes (e.g., events, changes in medication) occurring after completion of participation in the parent study that, in the investigator's judgment, would increase the risk of adverse events in this OLE study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Parent Study: GDC-0853

    Participants (who had received 50, 150 and 200mg GDC-0853 in Cohort 2 of the Parent GS39684 Study) received open-label fenebrutinib/GDC-0853 at a dose of 200mg orally twice a day.

    Drug: GDC-0853

  • Placebo comparator
    Parent Study: Placebo

    Participants (who had received Placebo in Cohort 2 of the Parent GS39684 Study) received open-label fenebrutinib/GDC-0853 at a dose of 200mg orally twice a day.

    Drug: GDC-0853

Interventions

  • Participants were administered GDC-0853 200mg orally, as per the dosing schedules described above.

    Also known as: fenebrutinib, RO7010939

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs)

    An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An Adverse Event can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as Adverse Events.

    Time frame: Baseline up until 4 weeks after the last dose of study drug (up to 10 months).

Secondary outcomes

  1. Plasma Concentrations of Fenebrutinib (GDC-0853) at Specified Timepoints

    Plasma Concentration Data for fenebrutinib (GDC-0853) will be tabulated and summarised by visits. Descriptive summary statistics for Arithmetic Mean and Standard Deviation will be presented.

    Time frame: Week 1 Day 1; Weeks 12 and 24; Study Completion/Early Discontinuation

07

Results

Posted Sep 25, 2020
Limitations and caveats
Recruitment was stopped after an interim analysis of the parent GS39684 study.

Participant flow

The study was conducted at 9 centers in 1 country.

Participant flow — Overall Study
MilestoneParent Study: GDC-0853Parent Study: Placebo
Started238
Completed00
Not completed238
Withdrew: Adverse event20
Withdrew: Study terminated by sponsor207
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryPercentage of Participants With Adverse Events (AEs)

An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An Adverse Event can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as Adverse Events.

Time frame:
Baseline up until 4 weeks after the last dose of study drug (up to 10 months).
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Events (AEs)
Percentage of ParticipantsParent Study: GDC-0853Parent Study: Placebo
Percentage of Participants With Adverse Events (AEs)60.962.5
SecondaryPlasma Concentrations of Fenebrutinib (GDC-0853) at Specified Timepoints

Plasma Concentration Data for fenebrutinib (GDC-0853) will be tabulated and summarised by visits. Descriptive summary statistics for Arithmetic Mean and Standard Deviation will be presented.

Time frame:
Week 1 Day 1; Weeks 12 and 24; Study Completion/Early Discontinuation
Reported as:
Mean · ng/mL
Plasma Concentrations of Fenebrutinib (GDC-0853) at Specified Timepoints
ng/mLParent Study: GDC-0853Parent Study: Placebo
Week 1 Day 1NA ± NANA ± NA
Week 12192 ± 181190 ± 278
Week 24130 ± 63.8467 ± 480
Study Completion/Early DiscontinuationNA ± NANA ± NA

Adverse events

Collected over Baseline up until 4 weeks after the last dose of study drug (up to 10 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Parent Study: GDC-08530/23 (0%)0/23 (0%)4/23 (17.4%)
Parent Study: Placebo0/8 (0%)0/8 (0%)5/8 (62.5%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventParent Study: GDC-0853Parent Study: Placebo
INCREASED TENDENCY TO BRUISEBlood and lymphatic system disorders0/231/8
DIARRHOEAGastrointestinal disorders0/231/8
DYSPEPSIAGastrointestinal disorders0/231/8
GASTROOESOPHAGEAL REFLUX DISEASEGastrointestinal disorders0/231/8
ABSCESS LIMBInfections and infestations0/231/8
ORAL HERPESInfections and infestations0/231/8
SKIN INFECTIONInfections and infestations0/231/8
ALANINE AMINOTRANSFERASE INCREASEDInvestigations1/231/8
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations1/231/8
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations1/231/8

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Parent Study: GDC-0853Parent Study: PlaceboTotal
Mean45.7 ± 16.540.8 ± 11.044.5 ± 15.3
Sex: Female, Male
Sex: Female, Male(Participants)Parent Study: GDC-0853Parent Study: PlaceboTotal
Female19625
Male426
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Parent Study: GDC-0853Parent Study: PlaceboTotal
Hispanic or Latino448
Not Hispanic or Latino19322
Unknown011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Parent Study: GDC-0853Parent Study: PlaceboTotal
Asian112
Black or African American213
White20626
08

Study locations

10 sites
  • Clinical Research Center of Alabama, LLC
    Birmingham, Alabama 35209, United States
  • Allergy & Asthma Immunology Associates
    Scottsdale, Arizona 85251, United States
  • Kern Allergy Med Clinic, Inc.
    Bakersfield, California 93301, United States
  • Southern California Research Center
    Mission Viejo, California 92691, United States
  • Allergy & Asthma Consultants
    Redwood City, California 94063, United States
  • Integrated Research Group Inc
    Riverside, California 92506, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Vital Prospects Clinical Research Institute PC - CRN
    Tulsa, Oklahoma 74136, United States
  • Asthma, Nasal Disease, and Allergy Research Center of New England
    East Providence, Rhode Island 02914, United States
  • Timber Lane Allergy and Asthma Research, LLC
    Burlington, Vermont 05403, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Oct 2019, 12 months.

Results were first posted in Sep 2020, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2018
First posted
Oct 3, 2018
StartActual
Sep 27, 2018
Primary completionActual
Oct 23, 2019
CompletionActual
Oct 23, 2019
Results first posted
Sep 25, 2020
Last update
Sep 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03693625
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Oct 3, 2018
Start date
Sep 27, 2018
Primary completion
Oct 23, 2019
Completion
Oct 23, 2019
Results posted
Sep 25, 2020
Last update
Sep 25, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenebrutinib

Start the discussion